INFORMATION FOR
News
In an interview, Rachel Perry, PhD, discusses the link between insulin and cancer, a surprising finding in her research, and the future of precision medicine for metabolism-related cancers.
Smilow Shares with Primary Care: Breast Cancer
Eric Winer, MD, the director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital in New Haven, Connecticut, tells SELF that there’s not quite a consensus on when cis women and people assigned female at birth should begin getting mammograms.
Monica G. Valero, MD, assistant professor of surgery (oncology) and director of the Hispanic Breast Cancer Program, has received a prestigious one-year pilot grant from the American Cancer Society (ACS) to advance breast cancer care among the Hispanic population. The prestigious award affirms the Department of Surgery’s commitment to tackling health inequities on a national scale and locally.
Smilow Cancer Hospital, in partnership with the Norma Pfriem Breast Center, has opened a new patient care location in Bridgeport, CT to provide residents in the greater Bridgeport area with convenient access to Smilow Cancer Hospital specialty breast surgical care and expertise.
The Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center provides coordinated, state-of-the-art care for patients with benign and malignant diseases of the breast.
Maryam Lustberg, director of the Center for Breast Cancer and chief of breast medical oncology at Yale Cancer Center and Smilow Cancer Hospital, says some promising advancements are already underway.
Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented at the 2023 San Antonio Breast Cancer Symposium.
New research illustrates remarkably lower use of immediate breast reconstruction in older women of Asian descent.
In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
A team of researchers led by senior author Dr. David Rimm and first author Charles “Jack” Robbins at Yale Cancer Center evaluated a new “selective” biomarker called Troplex™, which assesses HER2, TROP2, and cytokeratin using quantitative immunofluorescence.
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9.
Association for Clinical Oncology says the program was informed by feedback from a pilot involving 500 oncologists, including a pilot site at Smilow Cancer Hospital and Yale Cancer Center.
After Beating Cancer, Climbing Mt. Kilimanjaro was a Walk in the Park for Jennifer Smith
Ilana Richman, MD, MHS, assistant professor of medicine (general internal medicine), discusses breast cancer screening for women over the age of 75.
On October 26, 2023, the last Smilow Shares in a four-part CME series in honor of Breast Cancer Awareness Month was held on the topic of Recent Advances and Clinical Trials. Hosted by Bohdan Pomahac,
Drs. Mehra Golshan and Parisa Lotfi discuss when women should start getting mammograms.
The recommendation from Dr. Mehra Golshan, deputy chief medical officer for surgical services at Yale Cancer Center, is to start getting mammograms at 40, and to do it yearly.
Dr. Maryam Lustberg on Yale Cancer Answers.
Paris Butler, MD, MPH, participates in a Q&A for Breast Cancer Awareness Month.